Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Tables)

v3.21.2
Non-Controlling Interests (Tables)
9 Months Ended
Sep. 30, 2021
Non-Controlling Interests  
Schedule of Non-Controlling Interests in Consolidated Entities

Non-controlling interests in consolidated entities are as follows:

    

    

For the Nine Months Ended

    

    

    

    

 

As of September 30, 2021

September 30, 2021

As of September 30, 2021

 

Net loss attributable to

Non-controlling interests

Non-controlling

 

($ in thousands)

    

NCI equity share

non-controlling interests

in consolidated entities

ownership

 

FBIO Acquisition Corp VIII

$

(247)

$

(131)

$

(378)

 

32.0

%

Aevitas

(4,049)

 

(751)

 

(4,800)

 

45.9

%

Avenue 2

 

2,058

 

(2,182)

 

(124)

 

77.5

%

Baergic

 

(1,995)

 

(29)

 

(2,024)

 

39.5

%

Cellvation

 

(1,400)

 

(100)

 

(1,500)

 

22.1

%

Checkpoint 1

 

59,574

 

(20,618)

 

38,956

 

81.2

%

Coronado SO

 

(290)

 

 

(290)

 

13.0

%

Cyprium

 

(1,276)

 

(623)

 

(1,899)

 

29.8

%

Helocyte

 

(5,401)

 

(65)

 

(5,466)

 

18.3

%

JMC

 

886

 

(2,339)

 

(1,453)

 

7.2

%

Mustang 2

 

136,441

 

(35,787)

 

100,654

 

82.4

%

Oncogenuity

(581)

 

(555)

 

(1,136)

 

24.9

%

Tamid

 

(730)

 

 

(730)

 

22.8

%

Total

$

182,990

$

(63,180)

$

119,810

 

  

    

For the twelve months ended

    

    

 

As of December 31, 2020

December 31, 2020

As of December 31, 2020

 

Net loss attributable to 

Non-controlling interests 

Non-controlling 

 

($ in thousands)

    

NCI equity share

    

non-controlling interests

    

 in consolidated entities

    

 ownership

 

FBIO Acquisition Corp VIII

$

(7)

(27)

$

(34)

 

10.0

%

Aevitas

(2,370)

(823)

 

(3,193)

 

39.0

%

Avenue 2

 

5,800

(3,974)

 

1,826

 

77.4

%

Baergic

 

(1,662)

(97)

 

(1,759)

 

39.5

%

Cellvation

 

(1,089)

(182)

 

(1,271)

 

22.1

%

Checkpoint 1

 

41,704

(13,265)

 

28,439

 

80.4

%

Coronado SO

 

(290)

 

(290)

 

13.0

%

Cyprium

 

567

(1,478)

 

(911)

 

30.5

%

Helocyte

 

(4,986)

(259)

 

(5,245)

 

18.8

%

JMC

 

138

491

 

629

 

7.1

%

Mustang 2

 

116,060

(36,429)

 

79,631

 

80.9

%

Oncogenuity

(82)

(376)

 

(458)

 

25.3

%

Tamid

 

(663)

(40)

 

(703)

 

22.8

%

Total

$

153,120

$

(56,459)

$

96,661

 

Note 1:

Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2:

Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.